ReviewTherapeutic advances in chronic disease2016
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.
Review in Therapeutic advances in chronic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 3 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- Romanian clinical guideline for diagnosis and treatment of COPD.The Journal of international medical research · 2020Guideline
- Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.Respiratory research · 2019Pooled it
- Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2018Pooled it
- The efficient use of smartphone apps to improve the level of asthma knowledge.Journal of medicine and life · 2022Trial
- Assessment of risk factors responsible for rapid deterioration of lung function over a period of one year in patients with chronic obstructive pulmonary disease.Scientific reports · 2021Trial
- Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.Respiratory research · 2020Trial
- SputumInternational journal of chronic obstructive pulmonary disease · 2019Trial
- Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.Allergy · 2026Review
- The role of objective testing in urban adolescents with asthma symptoms in an African centre.BMC pediatrics · 2026Article
- Observational
- Beyond Eosinophil Depletion: IL-5 as a Context-Dependent Regulator of Airway Immune Networks.International journal of molecular sciences · 2026Review
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Ameliorating Effects ofAntioxidants (Basel, Switzerland) · 2026Article
- Short-Term Effects of Dupilumab in Eosinophilic COPD.Journal of clinical medicine · 2026Article
- Crystalline Insights into Nasal Mucosa Inflammation and Remodeling: Unveiling Role of Galectin-10.Biomolecules · 2026Article
- Article
- Association of Blood Eosinophil Counts with Expiratory Airflow Limitation: A Multi-Ethnicity Observational Study.Journal of inflammation research · 2026Article
- Effectiveness of Benralizumab in Reducing Asthma and COPD Exacerbations in Patients with Severe Asthma and Concomitant COPD: Real-World Evidence from the ZEPHYR-5 Study.International journal of chronic obstructive pulmonary disease · 2026Article
- A novel method to assess airway eosinophilia using sputum plugs.ERJ open research · 2026Article
- Biological treatments for asthma and chronic obstructive pulmonary disease.BMJ medicine · 2026Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The chronic lung diseases, asthma and chronic obstructive pulmonary disease (COPD), are common affecting over 500 million people worldwide and causing substantial morbidity and mortality. Asthma is typically associated with Th2-mediated eosinophilic airway inflammation, in contrast to neutrophilic inflammation observed commonly in COPD. However, there is increasing evidence that the eosinophil might play an important role in 10-40% of patients with COPD. Consistently in both asthma and COPD a sputum eosinophilia is associated with a good response to corticosteroid therapy and tailored strategies aimed to normalize sputum eosinophils reduce exacerbation frequency and severity. Advances in our understanding of the multistep paradigm of eosinophil recruitment to the airway, and the consequence of eosinophilic inflammation, has led to the development of new therapies to target these molecular pathways. In this article we discuss the mechanisms of eosinophilic trafficking, the tools to assess eosinophilic airway inflammation in asthma and COPD during stable disease and exacerbations and review current and novel anti-eosinophilic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.